SuperworthPMV Pharmaceuticals PMVP
- Market cap
- $67.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −105.0%
PMV Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $13.6M−1% | $13.4M−11% | $13.2M−13% | $14.6M+6% | $16.9M+25% | $13.8M+3% | $17.4M+32% | $18.4M+26% | $18.2M+8% | $15.8M+15% | $15.3M−12% | $14.7M−20% |
| SG&A | $6M+6% | $5.5M−10% | $5M−21% | $5.5M−12% | $4.9M−18% | $11.4M+107% | $4.1M−18% | $4.5M−19% | $4.3M−13% | $3.4M−70% | $3.7M−11% | $4.2M−6% |
| −$19.6M+1% | −$18.9M−11% | −$18.2M−15% | −$20.2M+0% | −$21.9M+12% | −$25.2M+33% | −$21.6M+18% | −$22.9M+13% | −$22.5M+3% | −$19.2M−24% | −$19M−12% | −$18.9M−18% | |
| Pre-tax income | −$16.6M−9% | −$15.8M−19% | −$15.3M−20% | −$17.4M−0% | −$19.2M+15% | −$23M+46% | −$19.6M+29% | −$21.2M+22% | −$21.1M+10% | −$18M−22% | −$18M−8% | −$18.1M−15% |
| −$1K−89% | −$1K | n/a | −$16.2M | $74K | $0 | −$2.2M | $5K | −$6K | $26K | n/a | $3K−40% | |
| Net income | −$16.6M−9% | −$15.8M−19% | −$15.3M−20% | −$1.2M−93% | −$19.2M+16% | −$23M+46% | −$17.4M+14% | −$21.2M+1649% | −$21.1M+10% | −$18M−22% | −$18M+4% | −$18.1M−15% |
| −$0.34−15% | −$0.31−26% | −$0.30−29% | −$0.02−95% | −$0.37+9% | −$0.44+42% | −$0.34+13% | −$0.41+1950% | −$0.40+8% | −$0.34−23% | −$0.34+0% | −$0.34−17% | |
| 49M+8% | 51.4M+12% | 51.4M+12% | 51.5M+12% | 51.6M+5% | 51.8M+1% | 52M+1% | 52M+1% | 53M+3% | 53.2M+3% | 53.3M+3% | 53.4M+3% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest PMV Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PMVPPMV Pharmaceuticals | $67.9M | n/m | n/a | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| Peer median | $477.3M | 10.5× | 12.3× | 1.4× | +2% | 13.6% |
More on PMV Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .